RCT: Tislelizumab vs. chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma.

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study – Journal of Clinical Oncology

Commentary on Twitter

In the phase III RATIONALE-302 trial of tislelizumab vs chemotherapy as 2nd-line therapy for advanced-stage ESCC, mOS was 8.6 vs 6.3 months (HR 0.70; P=0.0001), rising to 10.3 vs 6.8 months for those with a PD-L1 tumour area positivity score >10%: https://t.co/CNxads2Kn2 #esocsm

— NatureRevClinOncol (@NatRevClinOncol) April 27, 2022